查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853463

肿瘤NGS市场按产品类型、癌症类型、应用和最终用户划分－2025-2032年全球预测

Oncology NGS Market by Product Type, Cancer Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肿瘤 NGS 市场将成长至 16.5064 亿美元，复合年增长率为 15.97%。

主要市场统计数据
基准年 2024 5.0437亿美元
预计年份：2025年 5.8357亿美元
预测年份：2032年 16.5064亿美元
复合年增长率 (%) 15.97%

全面阐述临床定序创新、监管演变和营运协调如何融合，重新定义肿瘤学决策。

新一代定序 (NGS) 已从实验室专属技术发展成为癌症研究、诊断和治疗开发的核心支柱。高性能仪器的引入、日益完善的生物资讯流程以及检验的临床检测方法，使得分子谱分析能够指导诊断、预测治疗反应并监测微小残留病灶。随着技术的融合，实验室和临床团队正在采用连续定序，从标靶基因panel到全面的EXOME子组和转录组分析，不断拓展从患者样本中获得的可操作资讯的范围。

随着科技的日趋成熟，监管管道和报销机制也日趋完善，促使检测验证与临床效用证据的产生更加紧密地结合。因此，相关人员正增加对营运流程、品管系统和资料管治的投入，以确保分析效能能够转化为可重复的临床价值。这种环境形成了一个良性循环：检测可靠性和解读框架的提升推动了临床应用，而临床应用反过来又产生了支持NGS广泛融入标准诊疗流程的真实世界证据。

鑑于科学的快速发展和医疗保健奖励机制的不断变化，各机构必须在短期营运调整与平台灵活性、试剂供应稳定性以及可扩展的生物资讯学方面的策略投资之间取得平衡。以下章节概述了变革性转变、政策影响、竞争考察、区域动态、竞争洞察、实用建议以及支撑本分析的调查方法严谨性。

定序、资讯学和多组体学整合的技术进步如何重塑肿瘤学的诊断工作流程和临床决策流程

在技​​术进步、数据整合和不断演进的临床范式的推动下，肿瘤定序领域正在经历变革。短读长定序平台持续优化成本和通量，而长读长定序和单分子定序方法则显着提升了以往难以分析的结构变异和复杂基因组区域的表征能力。同时，检测设计也从广泛的探索性检测转向以临床为导向，优先关注可操作的变异和预测性生物标记物，从而更快地转化为治疗方法的选择。

资讯学已成为一项核心差异化优势，云端原生流程、容器化工作流程和机器学习辅助的变异解读提高了周转时间和解读的一致性。这些能力与标准化报告架构的结合日益紧密，从而增强了不同机构间的可比较性。同时，去中心化趋势正在加速发展。为了满足多样化的临床需求并加快结果出炉速度，实验室正在采用照护现场和床边检测策略，以补充集中式、高效能的营运。

最后，将包括RNA定序和表观遗传特征在内的多组学资料与临床和影像资料集整合，正在加速新型生物标记的发现和更精细的风险分层。因此，实验室和供应商正在将资源转向支援混合工作流程的模组化解决方案，以确保其投资在诊断模式不断演变的过程中保持有效性。

调整营运应对措施和筹资策略，以因应基于关税的供应链中断，并提高2025年总到岸成本的透明度

政策变革和贸易行动会对整个诊断生态系统的供应链、成本结构和筹资策略产生重大影响。 2025年美国关税政策为依赖全球化生产和复杂组件采购的实验室、试剂生产商和仪器供应商带来了新的考量。这些变化促使企业领导者重新评估供应商多元化、库存管理和物流计划，以降低跨境成本波动和潜在交货延迟的风险。

为此，许多企业正在加快对替代供应商的资格审核，并调整库存策略以确保服务不间断。产品负责人也评估在地化生产和组装的可行性，以减轻关税的影响。同时，合约谈判和服务水准协议也在进行修订，以纳入应对关税波动和海关相关中断的紧急条款。

重要的是，相关人员正优先考虑总落地成本计算的透明度和情境规划，以了解政策动态可能如何影响融资和经常性试剂支出。透过综合运用这些因应措施，动态旨在贸易政策加剧营运风险的环境下，既维持临床工作的连续性，也维持财务可预测性。

详细的细分洞察，包括产品类型、癌症类型、应用和最终用户，揭示了影响检测方法开发和商业化策略的差异化需求。

细分市场分析揭示了因产品类型、癌症类型、应用和最终用户而异的细微需求和机会领域。按产品类型划分，平台需要为分散式临床实验室使用的桌上型定序仪以及支援大规模集中式操作的高性能定序仪进行资本规划；试剂和耗材包括流动池、文库製备试剂套件和定序试剂套件，这些产品具有不同的保质期和低温运输要求；服务涵盖资料分析和样本製备服务，这些服务必须根据业务量和监管要求进行扩展。

乳癌的工作流程着重于荷尔蒙受体相关特征和拷贝数分析；结直肠癌着重于微卫星不稳定性及肿瘤突变负荷评估；骨髓恶性肿瘤着重于融合基因检测和克隆性分析；肺癌则需要敏感地检测低频驱动突变。每种癌症类型对检测设计、验证指标和临床报告的要求各不相同。

从应用角度来看，基因panel可提供精准、可操作的见解，并广泛用于选择标靶治疗。 RNA定序可检测基因表现和融合基因，从而增强对变异的解读和抗药性机制的阐明；而全EXOME显子定序则支持更广泛的发现应用、种系-体细胞分化以及复杂生物标记的开发。从最终用户的观点，学术研究机构优先考虑灵活性和发现能力；诊断实验室重视通量、可重复性和合规性；医院将定序整合到临床路径中，并需要具备营运弹性；而製药和生物技术公司则利用定序进行临床检测註册、伴随诊断开发和转化研究。这些相互交织的领域会影响产品定位、检验蓝图和商业化策略。

区域动态和监管差异将影响定序能力、报销模式和基础设施投资如何影响全球临床应用。

地理动态影响法律规范、报销环境和营运模式，揭示了影响技术应用和投资的区域优先事项。在美洲，完善的报销机制、成熟的参考实验室网路以及活跃的临床检测活动正在推动临床应用，支援集中式高效能定序和分散式诊断检测。该地区支付方、医疗服务提供者和创新者之间的持续互动正在加速实证医学证据的产生，并提高人们对临床有效性和效用的期望。

欧洲、中东和非洲地区监管环境和医疗保健资金筹措模式的差异，造就了错综复杂的局面，国家政策决策和区域合作倡议共同决定一体化的步伐。实验室必须因应不同的认证体系，并提供符合各国临床指引的检测服务。同时，该地区的相关人员正优先考虑数据标准的协调和互通性，以促进跨境研究和证据共享。

在亚太地区，定序基础设施的快速投资、国内试剂生产的扩张以及强大的临床检测体係正推动着定序技术的显着发展。多样化的医疗保健系统和不同程度的集中式实验室能力，既需要可扩展的高效能设施，也需要适应性强的桌上型解决方案。在所有地区，跨境合作、本地检验测试和监管协调对于加速将定序技术应用于常规癌症诊疗仍然至关重要。

竞争性创新、策略伙伴关係和能力整合如何推动肿瘤定序平台、试剂和服务供应商之间的差异化

企业间的竞争与合作动态正在塑造肿瘤定序生态系统的创新路径与服务产品。现有平台供应商持续投资于仪器性能、通量优化和整合软体，以降低临床应用门槛。同时，试剂和耗材专家则专注于供应链弹性、检测稳健性和跨多种仪器类型的相容性，以满足不同实验室的需求。服务供应商透过提供经过验证的生物资讯产品、承包到报告工作流程以及临床认证的实验室能力来脱颖而出，从而减轻医疗专业人员的负担。

共同开发契约正在加速伴随诊断项目的推进，并有助于更有效地对患者进行分层，从而进行治疗性检测。新兴企业正专注于满足未被满足的临床需求的细分领域，例如超灵敏液态切片检测、多组体学检测和人工智慧驱动的解读平台。同时，投资活动和有针对性的收购正在整合企业在规模和监管经验方面的能力，从而获得竞争优势。

在此趋势下，成功的公司正优先建构涵盖可重复性、法规遵循、培训、检测验证和上市后监测的客户支援体系。这些能力增强了临床医生和支付方的信心，并在临床证据和营运可靠性至关重要的市场中使供应商脱颖而出。

制定可操作的策略重点，协调平台模组化、生物资讯检验、供应链弹性以及相关人员参与，以加速临床应用。

为了保持市场竞争力并加速造福患者，产业领导者必须将技术前景转化为切实可行的、具有临床意义的解决方案。首先，投资于平台相容性和试剂互通性可以降低客户锁定风险，并增强应对供应链中断的能力。透过优先考虑模组化系统结构和开放资料实践，企业可以实现技术在各种异质实验室环境中的广泛应用。

其次，加强生物资讯学和解读能力至关重要。这意味着要投资检验的流程、标准化的变异註释框架以及以临床为中心的报告模板，从而缩短临床医生采取行动的时间。同样重要的是，要为临床医生开发教育计画和解读支持，将基因组学观察置于治疗路径中进行解读。

第三，领导者应制定正式的供应商多元化和区域化策略，以降低关税和物流风险。这可能包括寻找替代供应商、建立策略性库存缓衝，以及在可行的情况下考虑本地化生产和组装。此外，积极与监管机构和支付相关人员沟通，将确保证据的产生符合不断变化的临床效用和报销预期。

最后，采用以客户为中心的商业化策略，整合技术支援、检验服务和证据生成伙伴关係，将加速产品推广应用。透过使产品蓝图与临床工作流程和实验室要求保持一致，企业可​​以提供不仅科学先进，而且在操作和经济上都易于实现的解决方案。

采用严谨的混合方法，结合主要相关人员访谈、文献回顾、使用案例分析和三角验证，以获得可靠且透明的见解。

本报告的分析综合运用了多方面的证据，以确保其观点稳健可靠。主要研究包括与实验室主任、临床基因组学负责人、采购负责人和行业高管进行结构化咨询，以了解实践规范、验证要求和采购标准。此外，也对同侪审查文献、临床指南、监管文件和公开的技术文件进行了系统性回顾，从而提供有据可查的性能和临床有效性，以此作为技术评估的依据。

我们运用定量和定性三角测量法，整合不同来源的数据，并分析具有代表性的实验室实施方案，以深入了解工作流程优化、加快週转时间和品管实践。供应链和关税影响分析包括海关裁决、贸易政策分析以及与物流专家的访谈，旨在评估潜在的营运应对措施和缓解策略。

为确保透明度，调查方法详细记录了资料来源、访谈通讯协定、纳入标准和关键假设，并重点指出了监管时间表的区域差异和实验室认证标准的异质性等限制。在适用情况下，数据透过与专家进行后续访谈进行检验，并与技术规格和已发布的临床性能指标进行交叉核对。

全面分析技术成熟度、证据产生和供应链韧性将如何决定肿瘤定序常规临床整合的路径

总之，肿瘤特异性定序正处于曲折点，技术成熟度、数据整合和政策动态将共同决定其近期发展轨迹。定序化学和仪器设计的进步正在拓展分析能力，而资讯学和结果解读的改进则提高了其临床相关性。同时，与关税相关的供应链问题和区域监管差异要求进行周密的营运规划，以确保服务可靠交付。

这些措施包括投资于可互通的平台和检验的试剂，加强结果解读流程，确保供应链多元化，以及在证据开发早期阶段与监管机构和支付方进行沟通。对于临床实验室和医疗服务提供者而言，迫切需要将定序仪嵌入到可重复的工作流程和品质系统中，以便及时提供可操作的报告。对于开发人员和投资者而言，将产品开发与临床效用和监管准备工作相结合，以确保产品被广泛接受，是当务之急。

最终，将基因定序整合到常规肿瘤治疗中将是一个循序渐进且以实证医学主导。透过关注可重复性、临床影响和供应稳定性，相关人员可以加快基因定序的普及应用，从而将科学进步转化为可衡量的患者获益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将液态生物检体NGS检测整合到多种癌症类型的早期检测和治疗反应监测中
  • 采用结合基因组学和转录组学分析的综合肿瘤谱分析方案，以实现个人化肿瘤治疗决策。
  • 人工智慧驱动的生物资讯平台的出现，简化了科学研究和临床实验室对复杂癌症NGS资料集的解读。
  • 利用可携式定序仪扩展分散式NGS检测，可在资源匮乏地区实现照护现场肿瘤诊断。
  • 利用新一代定序技术（NGS）识别可操作突变以确定合格接受标靶治疗的伴随诊断技术取得了成长。
  • 加强製药公司与定序服务供应商之间的合作，以加速生物标记主导的药物研发
  • 整合表观遗传学和蛋白质组学数据的多体学NGS方法在更好地理解肿瘤异质性方面取得了进展
  • 人们越来越关注基于NGS的肿瘤检测的监管协调，以确保其全球市场进入和标准化。

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 按产品类型分類的肿瘤NGS市场

  • 平台
    • 桌上型音序器
    • 高通量定序仪
  • 试剂和耗材
    • 流动池
    • 图书馆调音套件
    • 定序试剂套件
  • 服务
    • 数据分析服务
    • 样品製备服务

第九章：按癌症类型分類的肿瘤NGS市场

  • 乳癌
  • 大肠直肠癌
  • 造血系统恶性肿瘤
  • 肺癌

第十章：肿瘤NGS市场应用

  • 基因检测
  • RNA定序
  • 全外EXOME定序

第十一章：肿瘤NGS市场（依最终用户划分）

  • 学术研究机构
  • 诊断实验室
  • 医院
  • 製药和生物技术公司

第十二章：肿瘤NGS市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：肿瘤NGS市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国肿瘤NGS市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • BGI Genomics Co., Ltd.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • PerkinElmer, Inc.
    • Eurofins Scientific SE
    • Guardant Health, Inc.
    • Sophia Genetics SA
Product Code: MRR-3A2E844FECAB

The Oncology NGS Market is projected to grow by USD 1,650.64 million at a CAGR of 15.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 504.37 million
Estimated Year [2025] USD 583.57 million
Forecast Year [2032] USD 1,650.64 million
CAGR (%) 15.97%

A comprehensive orientation to how clinical sequencing innovations, regulatory evolution, and operational readiness are converging to redefine oncology decision making

Next-generation sequencing (NGS) has moved from an experimental capability to a core pillar of oncology research, diagnostics, and therapeutic development. The introduction of high-throughput instruments, increasingly robust bioinformatics pipelines, and validated clinical assays has enabled molecular profiling to inform diagnosis, predict therapeutic response, and monitor minimal residual disease. As technologies converge, laboratories and clinical teams are adopting sequencing across a continuum that spans targeted gene panels to comprehensive exome and transcriptome analyses, thereby expanding the scope of actionable insights derived from patient samples.

Alongside technological maturation, regulatory pathways and reimbursement conversations have become more sophisticated, prompting closer alignment between assay validation and clinical utility evidence generation. Consequently, stakeholders are investing in operational workflows, quality management systems, and data governance to ensure analytic performance translates into reproducible clinical value. This environment is creating a virtuous cycle: improved assay reliability and interpretive frameworks drive clinical adoption, which in turn generates real-world evidence that supports broader integration of NGS into standards of care.

Given the rapidly evolving science and shifting healthcare incentives, organizations must balance near-term operational readiness with strategic investments in platform flexibility, reagent supply resilience, and scalable bioinformatics. The following sections outline transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive considerations, pragmatic recommendations, and the methodological rigor underpinning the analysis.

How technological advances in sequencing, informatics, and multiomic integration are reshaping diagnostic workflows and clinical decision pathways in oncology

The oncology sequencing landscape is undergoing transformative shifts driven by technological breakthroughs, data integration, and evolving clinical paradigms. Short-read platforms have continued to optimize cost and throughput, while long-read and single-molecule approaches have advanced the characterization of structural variants and complex genomic regions that were previously refractory to analysis. Concurrently, assay design has shifted from broad, exploratory panels toward clinically focused content that prioritizes actionable variants and predictive biomarkers, enabling more rapid translation into therapeutic choices.

Informatics has emerged as a central differentiator, with cloud-native pipelines, containerized workflows, and machine learning-assisted variant interpretation improving turnaround times and interpretive consistency. These capabilities are increasingly coupled with standardized reporting frameworks that enhance cross-institutional comparability. At the same time, decentralization trends are accelerating: point-of-care and near-patient testing strategies are being piloted, complementing centralized high-throughput operations to meet diverse clinical needs and reduce time-to-result.

Finally, integration of multiomic data-including RNA sequencing and epigenetic signatures-with clinical and imaging datasets is catalyzing new biomarker discovery and refined risk stratification. As a result, laboratories and vendors are shifting resources toward modular solutions that support hybrid workflows, ensuring that investments remain relevant as diagnostic paradigms continue to evolve.

Operational responses and procurement strategies adapted to tariff-driven supply chain disruptions and increased total landed cost transparency in 2025

Policy changes and trade measures can materially affect supply chains, cost structures, and procurement strategies across the diagnostics ecosystem. Tariff actions in the United States in 2025 have introduced additional considerations for laboratories, reagent manufacturers, and instrument suppliers that rely on globalized production and complex component sourcing. These shifts have prompted operational leaders to reassess supplier diversification, inventory policies, and logistics planning to mitigate exposure to cross-border cost variability and potential delivery delays.

In response, many organizations have accelerated qualification of alternative suppliers and adjusted stocking strategies to maintain uninterrupted services. Procurement teams are increasingly specifying supplier redundancy and localized support as part of contracting criteria, while product developers are evaluating the feasibility of regionalized manufacturing or assembly to reduce tariff-related impacts. At the same time, contract negotiations and service-level agreements are being revisited to incorporate contingency clauses that address tariff volatility and customs-related disruptions.

Importantly, stakeholders are also prioritizing transparency in total landed cost calculations and scenario planning to understand how policy dynamics could influence capital procurement and recurring reagent expenditures. Through these combined responses, operators aim to preserve clinical continuity while maintaining financial predictability in an environment where trade policy represents an elevated operational risk.

Detailed segmentation insights revealing differentiated product, cancer-type, application, and end-user imperatives that shape assay development and commercialization approaches

Segment-level analysis reveals nuanced requirements and opportunity areas that vary by product type, cancer type, application, and end user. When examined through product type, platforms require capital planning for benchtop sequencers that serve decentralized clinical labs as well as high-throughput sequencers that underpin large centralized operations; reagents and consumables span flow cells, library preparation kits, and sequencing kits with distinct shelf-life and cold-chain demands; and services encompass data analysis services and sample preparation services that must scale with volume and regulatory expectations.

When viewed by cancer type, the diagnostic and therapeutic imperatives differ: breast cancer workflows emphasize hormone receptor-related signatures and copy-number analyses, colorectal cancer places a premium on microsatellite instability and tumor mutational burden assessments, hematological malignancies rely on fusion detection and clonality profiling, and lung cancer requires sensitive detection of low-frequency driver mutations. Each cancer type drives differentiated assay design, validation metrics, and clinical reporting priorities.

By application, gene panels deliver focused actionable insights and are widely used for targeted therapy selection, RNA sequencing provides expression and fusion detection that enhance variant interpretation and resistance mechanism elucidation, and whole exome sequencing supports broader discovery applications, germline-somatic differentiation, and complex biomarker development. From the perspective of end users, academic research institutes prioritize flexibility and exploratory capability; diagnostic laboratories focus on throughput, reproducibility, and regulatory compliance; hospitals integrate sequencing into clinical pathways and require operational resilience; and pharma and biotech companies leverage sequencing for trial enrollment, companion diagnostic development, and translational research. These intersecting segmentation axes inform product positioning, validation roadmaps, and commercialization strategies.

Regional dynamics and regulatory diversity shaping how sequencing capabilities, reimbursement models, and infrastructure investments influence clinical adoption globally

Geographic dynamics influence regulatory frameworks, reimbursement environments, and operational models, yielding distinct regional priorities that shape uptake and investment. In the Americas, clinical adoption is driven by established reimbursement pathways, a mature network of reference laboratories, and active clinical trial activity, which together support both centralized high-throughput sequencing and distributed diagnostic testing. Continuous interaction between payers, providers, and innovators in this region accelerates evidence generation while raising expectations for clinical validity and utility.

In Europe, Middle East & Africa, regulatory heterogeneity combined with divergent healthcare funding models fosters a mixed landscape in which national-level policy decisions and collaborative regional initiatives determine the pace of integration. Laboratories must navigate varied certification regimes and align assays with country-specific clinical guidelines. Meanwhile, stakeholders across this region emphasize harmonized data standards and interoperability to enable cross-border research and pooled evidence generation.

In the Asia-Pacific region, rapid investments in sequencing infrastructure, growing domestic reagent manufacturing, and strong clinical trial pipelines are driving significant momentum. Diverse healthcare systems and varying levels of centralized laboratory capacity create opportunities for both scalable high-throughput facilities and adaptable benchtop solutions. Across all regions, cross-border collaborations, local validation studies, and attention to regulatory alignment remain essential to accelerate the translation of sequencing into routine oncology care.

How competitive innovation, strategic partnerships, and capability consolidation are driving differentiation across platforms, reagents, and service providers in oncology sequencing

Competitive and collaborative dynamics among companies are shaping innovation pathways and service delivery across the oncology sequencing ecosystem. Established platform providers continue to invest in instrument performance, throughput optimization, and integrated software to lower barriers to clinical adoption. Meanwhile, reagent and consumable specialists are focusing on supply-chain resilience, assay robustness, and compatibility across multiple instrument types to appeal to diverse laboratory footprints. Service providers are differentiating through validated bioinformatics offerings, turn-key sample-to-report workflows, and clinically accredited laboratory capabilities that reduce burden for healthcare providers.

Strategic partnerships between technology vendors, clinical laboratories, and pharmaceutical developers are increasingly common, as co-development agreements accelerate companion diagnostic programs and enable more efficient patient stratification in therapeutic trials. Emerging companies are concentrating on niche areas such as ultra-sensitive liquid biopsy assays, multiomic panels, and AI-enhanced interpretation platforms that address unmet clinical needs. In parallel, investment activity and targeted acquisitions continue to consolidate capabilities where scale and regulatory experience deliver competitive advantage.

Across these dynamics, successful organizations are prioritizing reproducibility, regulatory readiness, and customer support infrastructure that spans training, assay validation, and post-market surveillance. These capabilities underpin trust among clinicians and payers and differentiate suppliers in a market where clinical evidence and operational reliability are decisive.

Actionable strategic priorities that align platform modularity, bioinformatics validation, supply resilience, and stakeholder engagement to accelerate clinical adoption

Industry leaders must translate technological promise into operationally viable, clinically meaningful solutions to retain market relevance and accelerate patient impact. First, investing in platform compatibility and reagent interoperability reduces customer lock-in risk and enhances resilience against supply-chain disruptions. By prioritizing modular system architectures and open-data formats, organizations can enable broader adoption across heterogeneous laboratory environments.

Second, strengthening bioinformatics and interpretation capabilities is essential. This means investing in validated pipelines, standardized variant curation frameworks, and clinically focused reporting templates that reduce time-to-action for clinicians. Equally important is the development of clinician-facing educational programs and interpretation support that contextualize genomic findings within treatment pathways.

Third, leaders should formalize supplier diversification and regionalization strategies to mitigate tariff exposure and logistics risk. This includes qualifying alternative vendors, building strategic inventory buffers, and exploring regional manufacturing or assembly where feasible. Additionally, proactive engagement with regulatory bodies and payer stakeholders will ensure that evidence generation aligns with evolving expectations for clinical utility and reimbursement.

Finally, adopting a customer-centric commercialization approach that bundles technical support, validation services, and evidence-generation partnerships will accelerate adoption. By aligning product roadmaps with clinical workflows and trial requirements, organizations can deliver solutions that are not only scientifically advanced but also operationally and economically accessible.

A rigorous mixed-methods approach combining primary stakeholder interviews, literature synthesis, case studies, and triangulation to ensure robust and transparent insights

The analysis underpinning this report combines multiple evidence streams to ensure a robust and defensible perspective. Primary research included structured consultations with laboratory directors, clinical genomics leads, procurement officers, and industry executives to capture operational realities, validation requirements, and procurement criteria. These inputs were complemented by a systematic review of peer-reviewed literature, clinical guidelines, regulatory filings, and publicly available technical documentation to ground technology assessments in documented performance and clinical relevance.

Quantitative and qualitative triangulation methods were applied to reconcile disparate data sources, while case-study analyses of representative laboratory implementations provided practical insights into workflow optimization, turnaround-time drivers, and quality-control practices. The assessment of supply-chain and tariff impacts incorporated customs rulings, trade policy analyses, and logistics expert interviews to evaluate potential operational responses and mitigation strategies.

To ensure transparency, the methodology documents data sources, interview protocols, inclusion criteria, and key assumptions, and highlights limitations such as variability in regional regulatory timelines and heterogeneity in laboratory accreditation standards. Wherever applicable, data were validated through follow-up interviews with subject-matter experts and cross-checked against technical specifications and published clinical performance metrics.

Synthesis of how technology maturation, evidence generation, and supply-chain resilience collectively determine the path to routine clinical integration of oncology sequencing

In sum, oncology-focused sequencing is at an inflection point where technical maturity, data integration, and policy dynamics collectively determine near-term trajectories. Advances in sequencing chemistry and instrument design are expanding analytic capabilities, while improvements in informatics and interpretation are enhancing clinical relevance. At the same time, tariff-related supply-chain considerations and regional regulatory heterogeneity require deliberate operational planning to sustain reliable service delivery.

Organizations that succeed will be those that couple technological leadership with disciplined operational strategies: investing in interoperable platforms and validated reagents, strengthening interpretation pipelines, securing diversified supply chains, and engaging regulators and payers early in evidence development. For clinical laboratories and healthcare providers, the imperative is to embed sequencing within reproducible workflows and quality systems that deliver timely, actionable reports. For developers and investors, the priority is to align product development with clinical utility and regulatory readiness to ensure uptake.

Ultimately, the integration of sequencing into routine oncology care will be incremental and evidence-driven. By focusing on reproducibility, clinical impact, and supply resilience, stakeholders can accelerate adoption in ways that translate scientific progress into measurable patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy NGS assays for early detection and monitoring of treatment response in diverse cancer types
  • 5.2. Adoption of comprehensive tumor profiling panels combining genomic and transcriptomic analysis for personalized oncology decisions
  • 5.3. Emergence of AI-driven bioinformatics platforms to streamline interpretation of complex cancer NGS datasets across research and clinical labs
  • 5.4. Expansion of decentralized NGS testing through portable sequencers enabling point-of-care oncology diagnostics in resource-limited settings
  • 5.5. Growth of companion diagnostic development using NGS to identify actionable mutations for targeted therapy eligibility
  • 5.6. Increasing collaboration between pharmaceutical companies and sequencing service providers to accelerate biomarker-driven drug development
  • 5.7. Advancements in multiomics NGS approaches integrating epigenetic and proteomic data for deeper understanding of tumor heterogeneity
  • 5.8. Rising focus on regulatory harmonization for NGS-based oncology tests to ensure global market access and standardization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology NGS Market, by Product Type

  • 8.1. Platforms
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High Throughput Sequencers
  • 8.2. Reagents And Consumables
    • 8.2.1. Flow Cells
    • 8.2.2. Library Prep Kits
    • 8.2.3. Sequencing Kits
  • 8.3. Services
    • 8.3.1. Data Analysis Services
    • 8.3.2. Sample Preparation Services

9. Oncology NGS Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Hematological Malignancies
  • 9.4. Lung Cancer

10. Oncology NGS Market, by Application

  • 10.1. Gene Panels
  • 10.2. Rna Sequencing
  • 10.3. Whole Exome Sequencing

11. Oncology NGS Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Pharma And Biotech Companies

12. Oncology NGS Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncology NGS Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncology NGS Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. Roche Holding AG
    • 15.3.4. BGI Genomics Co., Ltd.
    • 15.3.5. QIAGEN N.V.
    • 15.3.6. Agilent Technologies, Inc.
    • 15.3.7. PerkinElmer, Inc.
    • 15.3.8. Eurofins Scientific SE
    • 15.3.9. Guardant Health, Inc.
    • 15.3.10. Sophia Genetics SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ONCOLOGY NGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ONCOLOGY NGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLOGY NGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FLOW CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREP KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GENE PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMA AND BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GCC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GCC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 298. GCC ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 299. GCC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 300. GCC ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 301. GCC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 302. GCC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 303. GCC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. GCC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 307. GCC ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. BRICS ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. BRICS ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. BRICS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. BRICS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. BRICS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 330. BRICS ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 331. BRICS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 332. BRICS ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 333. BRICS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 334. BRICS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 335. BRICS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. BRICS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS ONCOLOGY NGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 341. G7 ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 342. G7 ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 343. G7 ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. G7 ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 345. G7 ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2018-2024 (USD MILLION)
  • TABLE 346. G7 ONCOLOGY NGS MARKET SIZE, BY PLATFORMS, 2025-2032 (USD MILLION)
  • TABLE 347. G7 ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 348. G7 ONCOLOGY NGS MARKET SIZE, BY REAGENTS AND CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 349. G7 ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 350. G7 ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 351. G7 ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. G7 ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. G7 ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 354. G7 ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 355. G7 ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 356. G7 ONCOLOGY NGS MARKET SIZE, BY